aap: First-time shareholder participation in the form of a share buyback following the sale of aap Biomaterials GmbH in financial year 2016
Berlin, (PresseBox) - aap Implantate AG (“aap”) announces that the stated partial distribution of proceeds to shareholders from last year’s sale of the subsidiary aap Biomaterials GmbH shall be implemented in form of a share buyback. Overall, the company intends to purchase up to 2.25 million aap shares by means of a voluntary public share buyback offer at an offer price of EUR 1.52 per aap share. The maximum total purchase price (including incidental costs), and thereby the amount which shall be distributed among shareholders, will accordingly be up to EUR 3.5 million. aap plans to redeem the shares acquired following the acceptance period. With the divestments of its subsidiary aap Biomaterials GmbH and the remaining stake in aap Joints GmbH in financial year 2016 aap has successfully completed the transformation into a pure player in trauma. The company now has a comprehensive IP-protected product and technology portfolio, as well as a strong liquidity position, and can take even better advantage of the growing global trauma market with its focused business model. As previously announced, aap will use part of the proceeds from the sale of aap Biomaterials GmbH to finance further growth and to distribute part of them to its shareholders. In the course of the transaction the company reported a total cash inflow of around EUR 34 million at 31 December 2016. After careful examination and consideration of the different options to distribute proceeds taking into account the company’s growth plans for the years ahead the Management Board and Supervisory Board have decided to distribute to aap shareholders up to EUR 3.5 million (including incidental costs) by means of a public share buyback. From the company’s viewpoint a public share buyback offer is a shareholder-friendly measure that does justice to the nature of an one-off special payout most likely. At the same time a share buyback followed by redeeming the shares takes into account the reduced size of the company and lower revenue streams following the recent divestments.“We are delighted to be able for the first time since aap went public in 1999 to give something back to our shareholders in the form of a share buyback programme,” said Bruke Seyoum Alemu, Chairman of the Management Board (CEO) at aap. “We are also convinced that in offering our shareholders a price that is significantly above the average price over the past 12 months we are making a fair and attractive offer.”The acceptance period starts on Tuesday, 20 June 2017, 00.00 hours (CEST) and ends on Monday, 10 July 2017, 24.00 hours (CEST). The offer document will be published before the start of the acceptance period on the corporate website of the company (www.aap.de) in the section “Investors / Share Buyback” as well as in the Federal Gazette under www.bundesanzeiger.de.After the successful completion of its transformation into a focussed trauma company aap will invest the major part of the proceeds from the sale of aap Biomaterials GmbH in further growth and the acceleration of its innovations such as the silver coating technology. The Management Board and Supervisory Board continue to consequently pursue the overarching target to unlock the inherent value of aap’s innovative product and technology base and thereby creating sustainable value for the company’s shareholders.